Neurology

Frexalimab demonstrated a favorable tolerability profile after approximately 1 year of treatment for individuals with relapsing disease.

Ofatumumab (Kesimpta; Novartis) demonstrated a sustained efficacy as a first-line, continuous treatment for patients recently diagnosed and treatment-naïve with relapsing multiple sclerosis.

Speaker Monica Diaz describes the detrimental impact climate change has on the transmission and increases in infectious disease cases.

The extension trial of atogepant demonstrated an 8.5-day improvement of monthly migraine days at weeks 13 through 16 and no new safety signals were observed.

In addition to oral administration, patients with partial-onset seizures can now take the antiseizure medication via a nasogastric tube if the tablet is crushed and mixed with water.

Linking strong anticholinergic medications to increased risk of dementia in older adults

Although there are medical considerations for patients with psychiatric conditions, prescribers must consider patient preference to increase adherence and effectiveness of contraception.

New approaches for treating all schizophrenia symptoms by modulating dopamine and glutamate in non-traditional ways.

Data for generalized anxiety disorders and cannabis use is scarce, but pharmacists can help educate patients on potential benefits and risks of cannabis usage.

Developments in glycine transporter type 1 inhibitors, D-amino acid oxidase inhibitors, and phosphodiesterase inhibitors are pushing schizophrenia research forward.

Despite the positive results demonstrated in a prior phase 2 trial, AMX0035 failed to meet the phase 3 trial’s primary end point in treating patients with amyotrophic lateral sclerosis.

The recent ODD for the utidelone injectable could offer another treatment option for patients with BCBM.

Investigators found that mRNA technology for the delivery of antibody therapeutics were used to target tau in Alzheimer disease and can be applied to other tau targets.

The results displayed a dramatic reduction in the individuals’ tumors within days after single treatment.

The manager of clinical pharmacy at UPMC Health Plan describes the significance of the pharmacist’s role in multiple sclerosis care and when collaborating with other health care providers.

Melatonin is linked to circadian rhythm, mitochondrial function, and neuroinflammation.

Zero relapses were reported among individuals that received ravulizumab-cwvz over the 73 weeks of treatment.

Pharmacogenomics could help streamline prescribing and dosing for psychiatric medications, avoiding the trial-and-error process common with these medications.

The FDA recommends the dosage of givinostat (Duvyzat; Italfarmaco, ITF Therapeutics) should be based on the individual’s body weight and administered twice daily with food.

The platform is a first-of-its-kind therapeutic approach to promote remyelination among individuals with relapsing/remitting multiple sclerosis.

The FDA is convening a committee to discuss phase 3 data after the planned action date, which delays drug availability to patients.

“I’m better than I was before I had long COVID, and in so many ways,” said a patient in an interview with Pharmacy Times.

If vorasidenib receives full approval, it would be a first-in-class target therapy to treat individuals with IDH-mutant gliomas.

Understanding differences in the various levodopa formulations and assisting with medication therapy management is a crucial role for pharmacists.

Monitoring metal ion concentrations and chelation therapy is hypothesized to alleviate symptoms and diseases caused by neuroinflammation.

Hospital pharmacists can play an important role in advocating for, designing, and implementing various policies to optimize care.

Adults diagnosed with coronary heart disease before age 45 have an especially increased risk of developing dementia, Alzheimer disease, and vascular dementia.

The pattern for the diminished learning curve, associated with elevated amyloid levels, was consistent across 3 memory tasks, with strongest results for recalling digit-signs and groceries prices.

Due to the observational nature of the study, the study authors said they cannot determine causal relationships between statins and cognitive decline for patients with Alzheimer disease.

From newsworthy moments to groundbreaking research, these were the most-read Alzheimer disease-related articles on Pharmacy Times in 2023.